Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | NSD2 | O96028 | 3/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | SNCA | P37840 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156485 | 0.86 | ALDH1A1 (0.49) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL1807954 | 0.82 | LMNA (0.56) | KMT2AMEN1 | |
| SCHEMBL343180 | 0.81 | CASP6 (0.53) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL29889996 | 0.81 | CASP6 (0.58) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL31255683 | 0.81 | CASP6 (0.58) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL429785 | 0.81 | CASP6 (0.58) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL10864839 | 0.80 | CASP6 (0.56) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL11155537 | 0.80 | CASP6 (0.56) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL3147761 | 0.80 | CASP6 (0.56) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 | |
| SCHEMBL5346617 | 0.80 | CASP6 (0.56) | CASP6ALDH1A1HSD17B10CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107012695-B | Penetrating fluid for ink jet textile printing, ink jet textile printing method, and ink jet textile printing apparatus | 精工爱普生株式会社 | 2020-08-07 | — | — | CN | disclosed |
| EP-2441806-B1 | PORPHYRAZINE COLORING MATTER, INK COMPOSITION, RECORDING METHOD, AND COLORED OBJECT | NIPPON KAYAKU KK (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2463345-B1 | Ink composition, recording method using the same and recorded material | SEIKO EPSON CORP (JP) | 2017-01-18 | — | — | EP | disclosed |
| EP-3015516-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | Nippon Kayaku Kabushiki Kaisha (JP) | 2016-05-04 | — | — | EP | disclosed |
| EP-2420538-B1 | PORPHYRAZINE DYE, INK COMPOSITION CONTAINING SAME, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8876273-B2 | Ink composition, ink jet recording method using the same and recorded material | SEIKO EPSON CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8857965-B2 | Ink compostion, recording method using the same and recorded material | SEIKO EPSON CORPORATION (JP) | 2014-10-14 | — | — | US | disclosed |
| US-8790458-B2 | Ink set and droplet ejection apparatus using the ink set | SEIKO EPSON CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8657433-B2 | Porphyrazine coloring matter, ink composition, recording method, and colored object | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2014-02-25 | — | — | US | disclosed |
| EP-2206747-B1 | ANTHRAPYRIDONE COMPOUND, SALT THEREOF, MAGENTA INK COMPOSITION AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20100221502-A1 | Anthrapyridone Compound and Salt Thereof, Magenta Ink Composition Containing the Anthrapyridone Compound, and Colored Article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100209678-A1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION AND COLORED PRODUCT | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2206747-A1 | ANTHRAPYRIDONE COMPOUND, SALT THEREOF, MAGENTA INK COMPOSITION AND COLORED BODY | Nippon Kayaku Kabushiki Kaisha (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100112218-A1 | NOVEL PORPHYRAZINE COLORING MATTER, INK, INK SET, AND COLORED PRODUCT | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2128202-A1 | NOVEL PORPHYRAZINE DYE, INK, INK SET, AND COLORED MATERIAL | Nippon Kayaku Kabushiki Kaisha (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-7223301-B2 | Anthrapyridone compound, water-based magenta ink composition and inkjet recording method | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20060219131-A1 | Anthrapyridone compound, aqueous magenta ink composition and inkjet recording method | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1626069-A1 | ANTHRAPYRIDONE COMPOUND, AQUEOUS MAGENTA INK COMPOSITION AND INKJET RECORDING METHOD | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2006-02-15 | — | — | EP | disclosed |
| EP-1315695-B1 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6600069-B2 | Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example | TELIK, INC. | 2003-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209678-A1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION AND COLORED PRODUCT | RB1, ATXN2, ATXN10 | CASP6 2834/4885ALDH1A1 1925/4885HSD17B10 1677/4885 |
| US-20100221502-A1 | Anthrapyridone Compound and Salt Thereof, Magenta Ink Composition Containing the Anthrapyridone Compound, and Colored Article | ABL1, ATXN2L, ANXA7 | CASP6 2033/4885ALDH1A1 2170/4885HSD17B10 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.